Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Yoon Suk Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5835-9417; OpenAlex author ID A5101590198. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 4 papers · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers · 2025: 2 papers

Papers 11

  1. Toward an individualized strategy in perioperative chemotherapy for pancreatic cancer. Co-author DOI 10.1038/s41416-025-03293-x↗
  2. Effectiveness and cost analysis of liposomal irinotecan in patients with pancreatic adenocarcinoma: a multicenter real-world study. Co-author DOI 10.1177/17588359251370492↗
  3. Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer. Co-author DOI 10.3389/fonc.2024.1510016↗
  4. The Trends and Outcomes of Initial Palliative Chemotherapy in Patients with Pancreatic Cancer in Korea Based on National Health Insurance Service Data. Co-author DOI 10.3390/jcm13113229↗
  5. Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1038/s41598-021-99647-5↗
  6. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and m… Co-author DOI 10.1038/s41598-019-52167-9↗
  7. Postoperative early thromboembolism as a prognostic indicator in patients with curatively resected pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2014.12.051↗
  8. Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/md.0000000000001012↗
  9. Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients. Co-author DOI 10.1111/cas.12744↗
  10. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma. First author DOI 10.3346/jkms.2015.30.3.259↗
  11. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who hav… Co-author DOI 10.1159/000356158↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Hyeok Hwang · 10 shared papers, 2013–2025 · strength 1.23
  2. Jong-Chan Lee · 5 shared papers, 2015–2025 · strength 0.82
  3. Sang Myung Woo · 4 shared papers, 2013–2025 · strength 0.72
  4. Dong Kee Jang · 3 shared papers, 2024–2025 · strength 0.68
  5. Young Ae Kim · 3 shared papers, 2024–2025 · strength 0.68
  6. Jung Won Chun · 3 shared papers, 2024–2025 · strength 0.68
  7. Jaihwan Kim · 6 shared papers, 2015–2021 · strength 0.51
  8. Jai Hoon Yoon · 1 shared paper, 2025 · strength 0.42
  9. Woo Jin Lee · 1 shared paper, 2025 · strength 0.25
  10. Jong-chan Lee · 1 shared paper, 2024 · strength 0.22
  11. In Kyeom Hwang · 3 shared papers, 2015 · strength 0.16
  12. Yoo‐Seok Yoon · 3 shared papers, 2015 · strength 0.16
  13. Ho‐Seong Han · 3 shared papers, 2015 · strength 0.16
  14. Jai Young Cho · 3 shared papers, 2015 · strength 0.16
  15. Hyung Woo Kim · 1 shared paper, 2015 · strength 0.06
  16. Haeryoung Kim · 1 shared paper, 2015 · strength 0.05
  17. Min Geun Lee · 1 shared paper, 2013 · strength 0.04
  18. Dong Uk Kim · 1 shared paper, 2013 · strength 0.04
  19. Sang Hyub Lee · 1 shared paper, 2013 · strength 0.04
  20. Ji Kon Ryu · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.